Amgen Inc. $AMGN Position Increased by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC lifted its position in Amgen Inc. (NASDAQ:AMGN) by 8.8% during the third quarter, Holdings Channel reports. The institutional investor owned 31,750 shares of the medical research company’s stock after buying an additional 2,578 shares during the quarter. Amgen comprises approximately 0.6% of Soltis Investment Advisors LLC’s investment portfolio, making the stock its 28th largest holding. Soltis Investment Advisors LLC’s holdings in Amgen were worth $13,383,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of AMGN. State Street Corp lifted its position in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the last quarter. Bank of America Corp DE purchased a new position in Amgen in the second quarter worth $1,831,903,000. Wellington Management Group LLP grew its holdings in Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after purchasing an additional 2,514,254 shares during the last quarter. BlackRock Inc. increased its position in shares of Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Amgen by 702.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after purchasing an additional 1,344,010 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN opened at $460.73 on Friday. The firm has a market capitalization of $249.08 billion, a PE ratio of 28.63, a price-to-earnings-growth ratio of 3.31 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $468.27. The company’s fifty day moving average price is $419.32 and its 200-day moving average price is $374.09.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities research analysts predict that Amgen Inc. will post 22.96 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.2%. Amgen’s dividend payout ratio is currently 62.65%.

Insider Transactions at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last three months. Corporate insiders own 0.85% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Analyst support: RBC Capital reaffirmed its Buy rating, while Goldman Sachs and TD Cowen also maintained Buy recommendations. The continued bullish view provides support ahead of earnings. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Rare-disease pipeline progress: Amgen reported Phase 3 data for dazodalibep in Sjögren’s disease, additional long-term UPLIZNA data in IgG4-related disease and other autoimmune conditions, and a diagnostic collaboration aimed at earlier rare-disease detection. The updates reinforce the company’s effort to expand growth beyond its established products. Rare Disease Updates
• Positive Sentiment: Dividend income: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, payable December 11 to shareholders of record November 20. The dividend supports the stock’s income appeal. Amgen Fourth-Quarter Dividend
• Neutral Sentiment: Earnings catalyst: Amgen will report third-quarter 2026 results after the market close on November 3, followed by a conference call. Analysts are focused on whether strong sales of products such as Repatha and TEZSPIRE can offset rising expenses, pricing pressure and biosimilar competition. Amgen Third-Quarter Results Announcement
• Negative Sentiment: Profitability concerns: Management has warned that spending will increase, while MariTide trials could consume substantial cash. Investors are assessing whether higher research and development costs and a CFO transition could pressure margins. Amgen Expense and Profit Outlook

Analyst Ratings Changes

A number of research firms have commented on AMGN. Wells Fargo & Company decreased their price target on Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a research note on Monday, October 12th. Cantor Fitzgerald boosted their price target on Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Canaccord Genuity Group boosted their price target on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Citigroup upped their price objective on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Finally, HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and decreased their price objective for the company from $445.00 to $425.00 in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $389.71.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.